Month: July 2017
Lupin Pharmaceuticals Inc. have made a horrendous error with their packaging which could mess up birth control plans for many women.
On 30th May 2017, Lupin Pharmaceuticals Inc. announced a recall for one lot of Mibelas 24 Fe (Norethindrone Acetate and Ethinyl Estradiol 1mg/0.02mg chewable and ferrous fumarate 75mg) tablets after a customer complained there had been a mix-up with the packaging, missing expiry dates and incorrect lot information.
There’s a concern that the mix-up could result in women taking chemically inactive pills on days when they should be taking active tablets, and therefore risk unintended pregnancy.
Read More “Packaging mix-up of birth control pills could lead to unintended pregnancies”
The pharmaceutical sector has been investigated by the Competition and Markets Authority (CMA) for suspected breaches of competition legislation for alleged unfair pricing. The allegations of unfair pricing could have a severe knock-on effect on the NHS which is already in a vulnerable state.
The investigation into the unfair pricing was opened in October 2016. A large degree of scrutiny and information gathering is usually completed before the CMA will come to a definitive conclusion as to whether the pharmaceutical company have breached competition laws – namely Chapter II of the Competition Act (CA) and Article 102 of the Treaty on the Functioning of the European Union (TFEU).
The key issue here though is whether unfair pricing is needlessly costing the NHS too much. If so, the repercussions for this – given the state of our NHS – could be significant.
Read More “Investigation into alleged unfair pricing of drugs and medicines supplied to the NHS”
Docetaxel, or more commonly known by its brand name Taxotere, is a medical drug used to treat cancer. The chemotherapy drug can be used to treat breast, head and neck, stomach, prostate and non small-cell cancerous cells.
For breast cancer patients it’s the most popular choice of treatment with 75% opting for Taxotere. However, it has since been revealed that manufacturers have not been quite so explicit with the effects the life-saving drug can have, and patients and physicians have reportedly been kept in the dark that Taxotere can cause permanent hair loss.
Read More “Breast cancer patients reportedly not being sufficiently warned about permanent side effects of Taxotere”
An American woman from the state of Pennsylvania is set to be paid $2.16 million (around £1.7 million) for injuries suffered after having a pelvic mesh device implanted.
The medical device was manufactured by Ethicon; a medical device branch of Johnson & Johnson.
Ms Margaret Engleman brought the lawsuit after she had the mesh implanted to treat her stress urinary incontinence (SUI). However, the mesh reportedly fused and eroded into her organs causing painful complications. Being fused into her organs, the mesh could not be surgically removed and continues to cause pain and urinary problems to this day.
Read More “Pelvic mesh victim wins $2.16 million from Johnson & Johnson’s Ethicon in the U.S.”